Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular intervention, with recurring news centered on electrophysiology and arrhythmia treatment. Company updates cover the MAGiC™ Magnetic Interventional Ablation Catheter, MAGiC Sweep high density mapping catheter, Genesis and GenesisX robotic magnetic navigation systems, and related clinical use in complex heart-rhythm procedures.
News also includes FDA and international regulatory clearances or approvals, hospital robotic heart-arrhythmia program launches, commercialization of cath-lab technologies such as Synchrony™ and SynX™, manufacturing and product-pipeline progress, material agreements, capital-structure updates, and periodic operating and financial results.
Stereotaxis (NYSE: STXS) reported Q1 2026 revenue of $6.3 million, down from $7.5 million a year earlier, with a 60% gross margin and net loss of $5.9 million.
The company received U.S. FDA approval for its MAGiC catheter in January and FDA clearance for its Synchrony digital OR system in April, and signed a definitive agreement to acquire Robocath. Cash stood at $14.6 million with no debt. Stereotaxis guides to double-digit 2026 revenue growth, expecting revenue above $40 million and more than $10 million in both Q3 and Q4.
Stereotaxis (NYSE: STXS) announced the first United States patients treated with MAGiC™, its robotically-navigated magnetic ablation catheter, following FDA PMA approval on April 22, 2026. The initial U.S. case, performed by Dr. Nathan McConkey, treated complex congenital heart disease via basilic vein access with no recurrence in the weeks after the procedure. MAGiC is indicated for mapping, pacing, and creating endocardial lesions to treat supraventricular tachycardias in congenital heart disease patients with limited conventional access.
The release highlights improved catheter stability, contact force, and energy delivery and positions MAGiC to expand minimally invasive ablation options for challenging anatomy.
Stereotaxis (NYSE: STXS) will report its first quarter 2026 financial results after U.S. market close on Tuesday, May 12, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments.
Dial-in numbers and a live/replay webcast will be available via the company’s investor relations website; a phone replay will be accessible for one month beginning about four hours after the call.
Stereotaxis (NYSE: STXS) announced a definitive agreement to acquire Robocath on April 15, 2026, combining magnetic navigation and mechanical robotics to target electrophysiology, interventional cardiology and neurointerventions.
The deal includes an upfront payment of $20 million, contingent payments up to $25 million, expected mid-2026 close, and estimated $2 million first-year revenue with breakeven by year three.
Stereotaxis (NYSE: STXS) announced FDA 510(k) clearance and commercial launch of the Synchrony system on April 6, 2026. Synchrony is a 55" 4K interventional lab display with ultra-low latency video, obsolescence protection, and cloud-based SynX for HIPAA/GDPR-compliant remote collaboration.
The company reiterated guidance of over $3 million in 2026 revenue from Synchrony placements independent of robotic systems and emphasized future AI-enabled applications and broader cath lab adoption.
Stereotaxis (NYSE: STXS) reported 2025 results: revenue $32.4M (up 20% YoY) and Q4 revenue $8.6M (up 36% YoY). Recurring revenue was $22.2M (up 21%) and system revenue $10.2M (up 18%). Gross margin was ~53% for full year; cash was $13.4M with no debt.
Company highlighted US and EU approvals for GenesisX, MAGiC, and MAGiC Sweep and provided 2026 guidance targeting >$40M revenue and double-digit growth.
Stereotaxis (NYSE: STXS) will release fourth quarter and full year 2025 financial results on Monday, March 9, 2026 after U.S. market close and host a conference call and webcast at 4:30 p.m. ET.
Investors can dial in using U.S./Canada number 800-715-9871 or international 646-307-1963 with pass code 8365695, and a webcast and one-month phone replay will be available via the company investor relations site.
Stereotaxis (NYSE: STXS) announced a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany, making it the first hospital in Germany to adopt the Genesis Robotic Magnetic Navigation System for arrhythmia care. Physicians have treated initial patients across a range of arrhythmias using the system.
Company executives and Klinikum Fürth clinicians highlighted improved precision, procedural stability, and reduced radiation exposure from less fluoroscopic confirmation. Stereotaxis noted its technology has been used in over 150,000 patients globally and said it will support the hospital's robotic heart rhythm practice.
Stereotaxis (NYSE: STXS) announced FDA approval on January 6, 2026 of the MAGiC™ Magnetic Interventional Ablation Catheter for robotic cardiac electrophysiology procedures.
The MAGiC catheter is robotically navigated for mapping, diagnostic pacing, and creating endocardial lesions to treat supraventricular tachycardia in patients with congenital heart disease when conventional manual navigation is limited.
The company highlighted MAGiC's precision, expanded access for complex/underserved patients, and prior global use of Stereotaxis technology in over 150,000 patients.
Stereotaxis (NYSE: STXS) will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, chairman and CEO, will join a fireside discussion on December 3, 2025 at 9:00 AM ET and will be available for one-on-one investor meetings that day.
The release notes the company is achieving key regulatory milestones and showing early commercial growth. Stereotaxis develops robotic systems for minimally invasive endovascular intervention and reports its technology has been used to treat over 150,000 patients. The company included standard forward-looking risk disclosures about regulatory timing, market acceptance, and other business risks.